Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/09/22
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/28/22
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022GlobeNewsWire • 07/21/22
Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater ChinaPRNewsWire • 07/03/22
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B ProgramGlobeNewsWire • 06/25/22
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022GlobeNewsWire • 06/08/22
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting DetailsGlobeNewsWire • 05/18/22
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 UncertaintyBenzinga • 05/12/22
Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat EstimatesZacks Investment Research • 05/05/22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/05/22
Vir Biotechnology, Inc. (VIR) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/28/22
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D DayGlobeNewsWire • 04/27/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIRPRNewsWire • 04/23/22
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022GlobeNewsWire • 04/21/22